Severe acute respiratory syndrome
Conditions
Interventions
A total of 140 (one hundred and forty) patients diagnosed with severe acute respiratory syndrome will be invited to participate in the study, and, after signing the informed consent form, they will be
Drug
V03.175.250
Sponsors
Universidade de São Paulo
Fundação de Amparo a Pesquisa do Estado de São Paulo
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Volunteers; Both genders; Admitted to the Emergency Department with diagnosis of Acute Respiratory Syndrome, presumed or confirmed; Age equal to or greater than 18 years; Informed consent form (ICF) signed by the patient or legal guardian.
Exclusion criteria
Exclusion criteria: Patients with known allergy to N acetylcysteine; Pregnant women; In need of immediate mechanical ventilation or Refusal or inability to obtain consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in in-hospital mortality in 5%, verified by medical record analysis, in patients receiving N-acetylcysteine compared to the group receiving Placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in 5% in the need for endotracheal intubation, verified by medical record analysis, in patients receiving N-acetylcysteine compared to the group receiving Placebo | — |
Countries
Brazil
Contacts
Public ContactJulio Alencar
Universidade de São Paulo
Outcome results
None listed